Form 4: Plus Therapeutics Director Greg Petersen Acquires Stock Options
SEC Form 4 Filing
Director Greg Petersen of Plus Therapeutics acquired stock options on February 18, 2025, according to a Form 4 filing.
Summary
- Greg Petersen, a director at Plus Therapeutics, acquired 40,122 stock options on February 18, 2025.
- The exercise price of these options is $1.18.
- The options vest monthly over 12 months from the grant date, or in full at the Issuer's 2026 Annual Stockholder Meeting, subject to continued service.
- The options expire on February 17, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's acquisition could be interpreted as a slightly positive signal.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of transaction: Greg Petersen acquired stock options. |
| 02/20/2025 | Date of Form 4 filing. |
| 2026 Annual Stockholder Meeting | Options vest in full at the Issuer's 2026 Annual Stockholder Meeting, subject to continued service. |
| 02/17/2035 | Expiration date of the stock options. |
Keywords
Stock Options, Form 4, Director, PSTV, Plus Therapeutics, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.